Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) decreased -2.92% and closed at $3.32 after opening 3.43 with the overall traded volume of 548,476.00 shares. The company’s Market capitalization reached to $118.56 million, $35.71 million outstanding shares. Its low price was $3.26 and highest price was $3.43. The Distance from 50 day Simple moving average was 4.42% and Distance from 200 day Simple moving average -25.32%.The EPS is -0.45.
Anavex Life Sciences Corp. (AVXL) announced a collaboration with Ariana Pharma (Cambridge, MA and Paris, France) to use Ariana’s proprietary KEM® (Knowledge, Extraction, Management) patient stratification technology to potentially accelerate ANAVEX 2-73’s Phase 2/3 Alzheimer’s clinical development timelines. KEM® is a comprehensive and FDA-tested clinical data analysis system that enables full exploitation of complex datasets including of smaller numbers of patients.
“We are very impressed with the rational and efficient clinical trial path Anavex has embarked upon by adopting population pharmacokinetics (PK) and adaptive trial design in its current ANAVEX 2-73 Phase 2a study in Alzheimer’s disease,” said Mohammad Afshar, CEO of Ariana Pharma. “Ariana has the expertise to fully support Anavex’s precision medicine approach to develop more effective treatments for devastating diseases including Alzheimer’s, Parkinson’s and Rett syndrome.”
Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) closed at $-1.34 after opening 20.69 with the overall traded volume of 542,155.00 shares. The company’s Market capitalization reached to $1.15 billion, $56.50 million outstanding shares. Its low price was $20.65 and highest price was $21.68. The Distance from 50 day Simple moving average was -9.02% and Distance from 200 day Simple moving average was -22.16%. The EPS is -4.45.
Portola Pharmaceuticals Inc (PTLA) develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral, once-daily Factor Xa inhibitor, which is in Phase III clinical trial for treating venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge; and Andexanet alfa, a recombinant protein that is designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor.